BDNF & Neuroplasticity

Also known as: PNB-0408

Dihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University. It is considered one of the most potent cognitive enhancers ever tested in animal models — reportedly 7 orders of magnitude more potent than BDNF at improving cognitive performance in rodent Alzheimer's models. Exclusively used by the research and biohacking community with no human clinical trial data available.

Also known as: ACTH 4-10, BDNF Spray, BDNF, Flow Spray

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro, MEHFPGP, 813 Da molecular weight) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s. The compound is derived from ACTH(4-10) — the 4-10 amino acid fragment of adrenocorticotropic hormone — with the addition of a Pro-Gly-Pro C-terminal tail that confers resistance to enzymatic degradation while preserving neurotropic activity. Critically, Semax retains the cognitive, neurotrophic, and neuroprotective effects of its ACTH parent while completely lacking the adrenal-stimulating hormonal activity. In other words, Semax works on the brain without activating the HPA axis or affecting cortisol production — a therapeutically ideal profile. Semax was patented in 1982 by Russian researchers and achieved regulatory approval in the Russian Federation in 2000, where it is prescribed at pharmacies for cerebrovascular disorders (ischemic stroke recovery), optic nerve disorders, minimal brain dysfunction in children (ADHD-like presentations), asthenia, and various cognitive complaints. It is available in two commercial strengths: 0.1% intranasal solution for cognitive-nootropic indications and 1% intranasal solution for stroke recovery and neurological deficits. In Western markets, Semax has never been submitted for FDA, EMA, or other major regulatory approval — a pattern common to Russian neuropeptides that lack patent protection and Western pharmaceutical sponsors. It circulates in US and European biohacking communities through research chemical peptide suppliers and is considered one of the most potent, best-tolerated nootropic compounds available. The pharmacology of Semax is genuinely notable and spans multiple neurological domains. At the molecular level, Semax elevates BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) expression in the brain, promotes dopaminergic and serotonergic signaling, potentiates endogenous enkephalin activity, and upregulates expression of neuroprotective genes. At the clinical level, it produces cognitive enhancement (attention, memory, executive function), mood elevation, stress tolerance, neuroprotection during ischemia, and accelerated recovery from neurological injury. Russian clinical trials in acute ischemic stroke — the best-documented Semax indication — show meaningful improvements in functional recovery when Semax is administered within 6-24 hours of stroke onset, likely through direct neuroprotection plus enhanced neurogenesis during recovery. The stroke literature is the only domain where Semax has truly rigorous clinical trial evidence (Gusev et al., 2005). In the biohacking and cognitive enhancement community, Semax has achieved a reputation as the "premier Russian nootropic" — often positioned alongside Selank, Noopept, Modafinil, and racetams in the advanced cognitive stack. Users typically report improvements in focus, working memory, verbal fluency, motivation, stress tolerance, and overall cognitive throughput. The effects are often described as "clean" — producing alertness and engagement without the jitters of stimulants, without the emotional blunting of SSRIs, and without the sedation of anxiolytics. Dose-response is relatively modest (300-900 mcg daily typical), onset is rapid (15-30 minutes after intranasal administration), and effects last several hours per dose. Chronic use over weeks produces accumulating cognitive and mood benefits that appear to outlast plasma presence. This entry covers Semax pharmacology, the genuinely rigorous Russian stroke evidence base, the more speculative cognitive enhancement applications, protocol considerations, and safety profile. It should be read as an educational reference — Semax is not FDA-approved, is distributed through gray-market channels with variable quality, and anyone considering use should obtain reliable product, start conservatively, and have realistic expectations. Cross-reference with Selank, DSIP, and Epithalon for Russian peptide context, and with Noopept, Piracetam, and Modafinil for broader nootropic comparisons.

Also known as: NASA-Semax, N-Acetyl Semax

Acetylated form of Semax peptide with improved stability and potency, used as a nasal spray for cognitive enhancement and neuroprotection.

Also known as: TP-7, Selank Spray

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro, 750 Da molecular weight) developed in the 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences as a synthetic analog of tuftsin — an immunomodulatory tetrapeptide (Thr-Lys-Pro-Arg) that is naturally cleaved from the Fc region of immunoglobulin G. The original tuftsin molecule has well-documented immunomodulatory and neurotropic effects but is rapidly degraded by peptidases in plasma, limiting its therapeutic utility. Selank adds a Pro-Gly-Pro tail to the tuftsin sequence, which confers resistance to enzymatic degradation while preserving pharmacological activity. In Russia, Selank has been approved since 2004 for the treatment of generalized anxiety disorder (GAD) and is available by prescription at pharmacies across the Russian Federation and several neighboring countries. It is marketed as a 0.15% intranasal solution under the brand name "Selank" (╨í╨╡╨╗╨░╨╜╨║) by Peptogen, a Moscow-based pharmaceutical company. In Western markets, Selank has never been submitted for FDA, EMA, or other major regulatory approval — not because of unfavorable data, but because the commercial pharmaceutical industry has no mechanism to profit from a peptide with an expired patent and no Western development sponsor. As a result, Selank circulates in the biohacking and peptide-curious community primarily as a "research chemical" through specialty peptide suppliers, where it is sold in intranasal spray or injectable formulations. The pharmacological profile of Selank is distinctive among anxiolytics. Unlike benzodiazepines, it does NOT cause sedation, cognitive dulling, tolerance, dependence, or withdrawal. Unlike SSRIs, it has rapid onset (within 30-60 minutes of intranasal administration) and effects that outlast plasma presence. Unlike buspirone, it does not require weeks of chronic dosing to manifest effects. The compound appears to work through modulation of multiple neurotransmitter systems simultaneously — GABAergic, serotonergic, dopaminergic, and endogenous opioid — producing what the Russian clinical literature describes as an "anxiolytic + nootropic" profile: the user feels calmer but also more mentally engaged, not sedated. This unusual combination has driven substantial interest in Western biohacking circles as an alternative or adjunct to conventional anxiety pharmacology. Selank has been studied in Russian clinical populations for over two decades with a consistent efficacy and safety pattern across roughly 30-50 published clinical papers. The evidence base is real but has important limitations: most trials are Russian-language, published in Russian journals, with small sample sizes (often 30-100 patients), and use Russian psychiatric rating scales rather than the validated Western instruments (GAD-7, HAM-A, Beck Anxiety Inventory) that would facilitate cross-validation. Western meta-analyses and systematic reviews are essentially nonexistent. The Russian regulatory approval is real and meaningful — Russian drug regulation, while different from FDA standards, does require efficacy and safety evidence — but it does not automatically translate to confidence in Western evidence-based medicine frameworks. For the biohacking community, Selank's appeal is the combination of (1) rapid-acting anxiolysis without sedation, (2) cognitive enhancement rather than dulling, (3) favorable safety profile across decades of Russian use, (4) non-addictive, non-dependence-producing pharmacology, and (5) intranasal delivery that is simple and needle-free. Its limitations are (1) thin Western evidence base, (2) variable quality from research chemical suppliers, (3) lack of FDA regulation or oversight, (4) modest effect magnitude in some users relative to expectations, and (5) cost relative to generic anxiety pharmacology. This entry covers the pharmacology, clinical evidence, practical use considerations, and honest framing of the evidence gaps. Cross-reference with Semax, DSIP, and Epithalon for a complete picture of the Russian research peptide landscape.

Also known as: P21

P-21 (also written P021, or Peptide 021) is a synthetic peptidergic compound derived from the neurotrophic region of ciliary neurotrophic factor (CNTF), designed to activate neurogenic and BDNF-producing pathways in the adult brain without triggering the activation of the CNTF receptor that causes the undesirable side effects (cachexia, muscle wasting) that limited CNTF itself as a therapeutic. The compound emerged from a translational neuroscience research program at the New York State Institute for Basic Research in Developmental Disabilities, where Khalid Iqbal and colleagues characterized a region of CNTF that was responsible for the pro-neurogenic and cognitive effects without the adverse peripheral effects, then synthesized short peptides containing that functional motif (Chohan et al., 2011; Blanchard et al., 2010). P-21 is a small peptide (variable reported sequence across preparations) that has been tested in multiple rodent models including normal aged mice, Alzheimer's disease transgenic mice (3xTg-AD, APP/PS1), and models of age-related cognitive decline. The reported effects include increased hippocampal neurogenesis, elevated BDNF and other neurotrophin expression in the hippocampus and cortex, improved performance on hippocampus-dependent learning tasks (Morris water maze, novel object recognition), and reductions in pathological markers in AD models (amyloid plaque burden, tau hyperphosphorylation, synaptic deficits) (Chohan et al., 2011; Kazim et al., 2014; Baazaoui & Iqbal, 2017; Bolognin et al., 2014). These findings have attracted interest from both legitimate academic research (the compound has been evaluated as a potential AD therapeutic) and from biohacker communities seeking cognitive enhancement interventions. The practical reality in April 2026 is that P-21 has not progressed to human clinical trials, has no FDA approval, has no published pharmacokinetic data in humans, and is sold as a research peptide by vendors with variable quality control. Self-experimenters typically administer P-21 intranasally as a spray or drops, which bypasses the blood-brain barrier concerns that complicate peptide CNS delivery, though intranasal bioavailability and tissue distribution in humans are not characterized. Subcutaneous and oral administration are less common for P-21 because the intended target is the central nervous system and systemic administration provides poor brain penetration for most peptides. Enthusiasm for P-21 in biohacker circles is driven partly by its mechanistic story (pro-neurogenic, BDNF-activating, with preclinical data in AD models) and partly by marketing that sometimes conflates rodent efficacy data with implied human benefit. The honest framing is that P-21 is a mechanistically interesting research compound with good preclinical data in narrow model systems and no human validation. FDA-approved interventions for cognitive concerns — addressing cardiovascular risk factors, treating depression and anxiety, hearing and vision correction, social engagement, cognitive stimulation, exercise, adequate sleep, and specific interventions for diagnosed conditions (cholinesterase inhibitors, memantine for AD dementia; SSRIs for depression-related cognitive symptoms) — have evidence bases orders of magnitude stronger than any research peptide for cognitive or neurological outcomes. P-21 sits in the experimental category and should be framed accordingly rather than positioned as a legitimate cognitive enhancer or AD prevention strategy. This entry covers what P-21 actually does in the preclinical literature, how the CNTF-derived mechanism works, what the limitations of the evidence are, what the theoretical and practical concerns are for human use, and what a realistic approach looks like for anyone considering experimentation with the compound.

NSI-189 is a novel synthetic compound developed by Neuralstem Inc. that stimulates neurogenesis in the human hippocampus. Phase 2 trials for major depressive disorder showed improvements in subjective cognitive function, depression scores, and positive affect despite not reaching primary endpoints. It has a dedicated following in the biohacking community for its reported hippocampal neurogenesis, emotional blunting reversal, and unique cognitive profile unlike any other nootropic.

TAK-653 is a novel positive allosteric modulator (PAM) of AMPA-type glutamate receptors developed by Takeda Pharmaceuticals. It enhances glutamatergic neurotransmission without directly activating the receptor, offering a more controlled mechanism for cognitive enhancement and antidepressant effects. Originally developed for treatment-resistant depression, it has gained interest in the research community for its potential nootropic and neuroplasticity-promoting properties.

Also known as: PE2228

PE-22-28 is a synthetic seven-amino-acid peptide (sequence PAGASRLLLLTGEIDLP derivative, commonly truncated to PE-22-28 as shorthand for "position 22-28" within the parent humanin-family sequence) that was designed as an analog of Humanin with specific interest in activity at glutamate transporter regulation and cytoprotective signaling relevant to depression and neuroprotection. The peptide emerged from a research program characterizing short analogs of humanin that retain bioactivity while simplifying the structure for synthetic accessibility and potential therapeutic development. PE-22-28 specifically attracted attention when preclinical work suggested antidepressant-like activity in rodent models of depression, with a proposed mechanism involving glial cell modulation and glutamate transporter 1 (GLT-1/EAAT2) regulation. The compound sits in the broader field of peptide-based neuropsychiatric therapeutics, alongside compounds like Selank and Semax that have been used in Russia for decades but remain investigational in Western markets. PE-22-28 is distinctive within this space because of its mechanistic grounding in humanin biology and glutamate homeostasis, which connects it to contemporary understanding of depression pathophysiology that emphasizes the role of glutamatergic signaling, astrocyte function, and neuroinflammation alongside the classical monoamine framework. The practical reality in April 2026 is that PE-22-28 remains a preclinical research peptide with limited published literature, no approved human use, no registered clinical trials, and a small but active self-experimentation community among biohackers interested in short peptide therapeutics for mood and cognitive applications. The compound is sold by research-chemical peptide vendors with the standard "for research purposes only" framing, and individual users have accumulated anecdotal experience with it in protocols typically involving daily or every-other-day subcutaneous dosing. The evidence base for PE-22-28 is substantially thinner than for BPC-157, Selank, or Semax in terms of published animal studies and translational groundwork; the peptide's profile rests on specific rodent behavioral studies and mechanistic biology inferred from its relationship to humanin and its proposed interactions with glutamate transporter regulation. This entry covers what is published about the peptide, the mechanistic rationale connecting it to humanin biology and glutamate homeostasis, the specific preclinical behavioral data that sparked interest in depression applications, realistic interpretation of that data in the context of the replication crisis in preclinical depression research, the theoretical and practical concerns with self-administration of a minimally characterized peptide, how PE-22-28 fits into the peptide stacking landscape alongside other cytoprotective and neuropsychiatric peptides, and what conservative thinking about this molecule looks like for someone considering it seriously rather than as a novelty.

Also known as: MB, MB Vape, Methylene Blue Vape

Methylene blue (methylthioninium chloride) is a phenothiazine dye with a 150-year pharmacology record. It was the first fully synthetic drug ever used in medicine (Ehrlich, 1891 for malaria) and remains on the WHO Model List of Essential Medicines as the first-line treatment for acquired methemoglobinemia. In the last decade it has re-emerged in biohacking circles because low doses (~0.5 to 4 mg/kg) act as an alternative mitochondrial electron carrier, bypassing damage at Complex I/III of the respiratory chain and boosting cytochrome c oxidase activity (Atamna et al., 2008). The molecule has an auto-oxidizing redox cycle: reduced leucomethylene blue donates electrons to cytochrome c, then the oxidized form accepts electrons from NADH, effectively forming a "shunt" around dysfunctional mitochondrial complexes. This is why low-dose MB improves cerebral oxygen consumption and memory performance in humans, while high doses paradoxically inhibit the same system — the dose-response curve is hormetic and inverted-U, one of the most-cited nootropic examples in the field. There are two entirely different use cases for methylene blue, and collapsing them is the most common cause of harm: Medical methemoglobinemia rescue (1-2 mg/kg IV): Life-saving antidote delivered by clinicians for nitrate/nitrite/benzocaine/dapsone poisoning. Non-negotiable pharmaceutical-grade material, hospital setting. Nootropic/mitochondrial microdosing (0.5-4 mg oral per day): Off-label self-experimentation. Requires USP pharmaceutical-grade only — not the industrial textile dye sold on aquarium or lab-chemistry sites, which contains arsenic, cadmium, mercury, and other heavy metals above safe intake thresholds. If a vendor cannot produce a third-party Certificate of Analysis showing USP purity (>99%) with heavy-metal testing, it is not safe for ingestion at any dose. See our Vendor COA Guide and Methylene Blue Complete Guide for sourcing protocol.

Lion's Mane (scientific name Hericium erinaceus; also known as yamabushitake in Japanese, houtou in Chinese, bearded tooth fungus, monkey head mushroom, and pom pom mushroom) is a white-to-cream coloured edible and medicinal mushroom in the tooth fungus family (Hericiaceae), characterised by its distinctive cascading spines that resemble a lion's mane or white cascading icicles. It grows on the wounds and dead trunks of deciduous hardwood trees (especially beech and oak) across temperate forests in North America, Europe, and Asia, and has been cultivated commercially in Japan, China, Korea, and increasingly in Western countries since the late 20th century. It has a long history in East Asian cuisine and traditional medicine — mentioned in Chinese medical texts for centuries and used in Japanese Buddhist traditions (particularly by the Yamabushi mountain priests, from which it takes its Japanese name) — with traditional claims around stomach/digestive health, vitality, and cognitive function. Chemically, Lion's Mane contains a complex mixture of bioactive compounds spanning polysaccharides (β-glucans), phenolic compounds, terpenoids, and — most importantly for nootropic purposes — two unique classes of compounds: hericenones (found primarily in the fruiting body, the above-ground mushroom part) and erinacines (found primarily in the mycelium, the underground root-like network). These compounds are believed to be the primary drivers of Lion's Mane's central nervous system effects. Fifteen hericenones (A-P) and numerous erinacines (A, B, C, E, J, P, Q, S and others) have been isolated and characterised, with different compounds present in different ratios depending on growth conditions, strain, and whether the extract comes from fruiting body or mycelium. The central mechanistic claim for Lion's Mane — and the basis for its position in the nootropic and neurological-health supplement space — is that hericenones and erinacines stimulate the synthesis of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF), two of the most important neurotrophic proteins supporting neuron survival, dendritic growth, synaptic plasticity, and peripheral nerve regeneration. NGF and BDNF are critical for maintaining healthy CNS function across the lifespan, and their decline is implicated in neurodegenerative diseases (Alzheimer's, Parkinson's), diabetic peripheral neuropathy, age-related cognitive decline, and various psychiatric conditions including major depression. A compound that can raise endogenous NGF/BDNF production — if it translates to meaningful clinical effect — would be of substantial therapeutic interest. The preclinical evidence for NGF/BDNF stimulation by Lion's Mane compounds is relatively strong. Mori, Kawagishi, Shimbo, and other Japanese researchers have published extensively on the NGF-stimulating effects of hericenones and erinacines in cell culture (PC12 cells, primary neuronal cultures) and rodent models of cognitive impairment. Erinacines, particularly erinacine A, cross the blood-brain barrier more efficiently than hericenones and show the strongest effects on brain NGF in animal studies. Multiple rodent models of Alzheimer's-type pathology, ischaemic brain injury, traumatic brain injury, and peripheral nerve crush injury have shown benefit from Lion's Mane extracts, with mechanistic data supporting NGF/BDNF involvement. The human clinical evidence is more modest. The most frequently cited human trial is Mori et al. 2009 (PMID: 18844328), published in Phytotherapy Research — a randomised, double-blind, placebo-controlled trial in Japanese adults aged 50-80 with mild cognitive impairment. Subjects received Lion's Mane fruiting body powder (3 g/day, containing hericenones) or placebo for 16 weeks. The Lion's Mane group showed statistically significant improvement on the revised Hasegawa Dementia Scale (HDS-R) compared with placebo at weeks 8, 12, and 16. Critically, the benefit disappeared after discontinuation (assessed at week 4 post-discontinuation), suggesting ongoing intake is needed to maintain any effect. The trial was small (n=30), conducted in one Japanese clinical setting, and used a cognitive scale more commonly applied in Japanese clinical practice than in Western cognitive research. It has not been replicated by independent Western research groups at scale. Other human evidence includes: Nagano et al. 2010 (PMID: 20834180) — small study (n=30) suggesting Lion's Mane reduced symptoms of anxiety and depression in menopausal women over 4 weeks; Saitsu et al. 2019 (PMID: 31787981) — small study (n=31) showing Lion's Mane extract (1.2 g/day containing amycenone) improved cognitive function and subjective sleep quality over 12 weeks in community-dwelling adults with self-reported cognitive complaints; and numerous smaller, less rigorous studies of peripheral neuropathy, peripheral nerve recovery, and various claims. The overall human evidence base is suggestive but not definitive — there is more human data for Lion's Mane than for most "natural" nootropics, but substantially less rigorous than for approved pharmaceuticals treating cognitive, psychiatric, or neurological conditions. Where does Lion's Mane fit honestly in the therapeutic landscape? For established Alzheimer's disease and related dementias, the evidence-based treatments are cholinesterase inhibitors (donepezil, rivastigmine, galantamine), memantine, and — for appropriate prodromal and early Alzheimer's patients — the newer disease-modifying antibodies lecanemab and donanemab. Lion's Mane is NOT a substitute for any of these treatments. For mild cognitive impairment and subjective cognitive decline in older adults, the evidence-based interventions are aerobic exercise, Mediterranean-style diet, cognitive engagement, social engagement, management of vascular risk factors, and optimisation of sleep and mood. Lion's Mane may have an adjunctive role in this context based on Mori et al. 2009 but is not an established treatment. For major depression, evidence-based options are SSRIs, SNRIs, bupropion, mirtazapine, and increasingly ketamine/esketamine for treatment-resistant cases — Lion's Mane is NOT a substitute. For peripheral neuropathy, evidence-based first-line treatments are SNRIs (duloxetine), gabapentinoids, tricyclic antidepressants, and topical agents — Lion's Mane has some preclinical rationale but limited human trial evidence for this indication. Where Lion's Mane may have a reasonable place is: (1) as a general cognitive-support supplement in older adults interested in a low-risk, natural option with modest supporting evidence; (2) as a component of broader nootropic stacks focused on neurotrophic support (often combined with uridine, choline sources, and DHA); (3) as a culinary mushroom with pleasant seafood-like flavour that incorporates potentially beneficial compounds into ordinary diet; (4) as an adjunct for occupational/functional cognitive demands in healthy adults seeking modest support with minimal risk. It is unlikely to produce dramatic cognitive effects and should not be positioned as such. Lion's Mane has one of the best safety profiles of any nootropic — it is a food item in Japan, China, Korea, and increasingly in Western cuisine, and has been consumed by humans for centuries without significant safety concerns. Allergic reactions have been reported, particularly in individuals with other mushroom allergies, but these are uncommon. It is generally regarded as safe for long-term daily use at typical supplemental doses. The supplement market for Lion's Mane has exploded in the 2020s, with products ranging from high-quality extracts with standardised hericenone/erinacine content to essentially worthless mycelium-on-grain products with minimal active compound content. Quality control is a significant issue: many commercial products are mycelium grown on grain substrate, harvested together with the grain, and marketed as "Lion's Mane" while containing predominantly starch/grain material with minimal mushroom content. Users seeking evidence-based use should look for fruiting body extracts with standardised polysaccharide content and — ideally — disclosed hericenone/erinacine content, though the latter is rarely provided by manufacturers.

Also known as: Brahmi, Water Hyssop, Herb of Grace, Thyme-leafed Gratiola, Jalanimba, Synapsa, CDRI-08, BacoMind, BioBM, Bacosides

Bacopa monnieri is a creeping, succulent-leaved aquatic perennial that grows in wetlands, bogs, and rice paddies across the Indian subcontinent, Southeast Asia, northern Australia, and the southern United States. Known as "Brahmi" in Sanskrit — a name it shares somewhat confusingly with Centella asiatica (gotu kola), which is also sometimes called Brahmi in certain Indian regions — Bacopa monnieri has been used in Ayurvedic medicine for at least 3,000 years as "medhya rasayana" (a mind-nourishing rejuvenative), with classical texts including the Charaka Samhita and Sushruta Samhita prescribing it for memory, concentration, anxiety, epilepsy, and mental clarity. Unlike the stimulating adaptogens (rhodiola rosea, panax ginseng) that produce acute wakefulness within days, or the calming adaptogens (ashwagandha) that modulate stress within weeks, Bacopa monnieri is the slowest-acting of the major adaptogens — most users experience no discernible effect in the first 4-6 weeks of dosing, with cognitive benefits emerging gradually at 8-12 weeks and continuing to deepen at 4-6 months of continuous use. This pharmacokinetic profile is not a flaw but a reflection of the mechanism: Bacopa's primary effects are structural (hippocampal dendritic arborization, synaptic density, long-term potentiation facilitation) rather than acute neurotransmitter modulation, and structural brain changes require weeks of consistent exposure before they become clinically measurable. The active constituents are the bacosides, a family of saponin glycosides comprising bacoside A (itself a mixture of bacoside A3, bacopaside II, bacopasaponin C, and jujubogenin) and bacoside B, along with bacopasides I through XII, bacopasaponins A-G, and minor flavonoids including apigenin and luteolin. Clinical trials have almost universally used extracts standardized to 50% bacosides, with the two most-studied proprietary extracts being BacoMind (Natural Remedies, India; used in the Morgan 2010 and Calabrese 2008 trials) and Synapsa / CDRI-08 (Central Drug Research Institute, Lucknow; used in the Stough 2001, Stough 2008, Roodenrys 2002, and Peth-Nui 2012 trials). Other extracts on the market include BioBM (Life Extension) and various 20% or 45% bacoside extracts from generic suppliers. The practical rule for consumers: buy only products standardized to 50% bacosides or a named proprietary extract with published clinical trials. Generic "Bacopa monnieri powder" at unverified standardization is unreliable because bacoside content varies 3-5x across wild-harvested or poorly cultivated material. The mechanism of action differs fundamentally from both rhodiola (monoamine modulation) and ashwagandha (HPA-axis and GABAergic). Bacopa's cognitive-improving profile emerges from at least six parallel mechanisms: (1) acetylcholinesterase (AChE) inhibition at modest potency, extending synaptic acetylcholine half-life in cortical and hippocampal circuits in a manner mechanistically similar to but far milder than donepezil; (2) brain-derived neurotrophic factor (BDNF) upregulation via CREB-mediated transcription, driving the trophic-structural changes that underlie long-term memory consolidation; (3) hippocampal CA1 dendritic arborization and spine density increase, demonstrated in rat models by Vollala and colleagues (2011) showing 30-40% increased dendritic branching after 6 weeks of bacopa feeding (PMID: 21741519); (4) antioxidant activity including superoxide dismutase induction and lipid peroxidation reduction, particularly in brain tissue where bacosides cross the blood-brain barrier efficiently; (5) mild anxiolytic activity via GABA-A receptor positive modulation and serotonin 5-HT1A partial agonism; and (6) cerebrovascular effects including increased cerebral blood flow and endothelial nitric oxide synthase upregulation, documented in older adults with mild cognitive impairment. Each mechanism is individually modest — Bacopa is not a potent AChE inhibitor like donepezil, not a strong BDNF inducer like exercise, not a structural neurogenesis driver like lion's mane — but their convergence produces a distinctive and reproducible cognitive phenotype centered on memory consolidation, information retention, and reduced cognitive decline with aging. Clinically, the evidence base is among the strongest for any herbal nootropic, with at least nine randomized placebo-controlled trials and a 2014 meta-analysis (Kongkeaw et al., PMID: 24252493) pooling 9 RCTs and concluding Bacopa monnieri produces significant improvements in cognitive performance with a pooled standardized mean difference of 0.21-0.31 across memory and attention domains. The seminal Western trial is Stough et al. 2001 (Neuropsychopharmacology), which randomized 46 healthy adults to 300 mg/day Bacopa (Synapsa/CDRI-08) versus placebo for 12 weeks and demonstrated significant improvements in information processing speed, learning rate, and memory consolidation by week 12 with no detectable effect at weeks 4 or 8 — the classic delayed-onset Bacopa profile (PMID: 11498727). Roodenrys 2002 extended this with a second RCT in 76 adults showing improved free recall and reduced learning-related forgetting (PMID: 12093601). Calabrese 2008 in the Journal of Alternative and Complementary Medicine randomized 48 older adults (mean age 73) to BacoMind 300 mg/day versus placebo for 12 weeks, finding significant improvements in word recall, delayed recall, Stroop task, and depression/anxiety subscales (PMID: 18521727). The elderly-response magnitude in Calabrese 2008 (effect size ~0.5) is larger than in the young-adult trials (effect size ~0.2-0.3), suggesting Bacopa's benefit scales with underlying cognitive vulnerability — older adults with age-related cognitive decline respond more robustly than healthy young adults. Where Bacopa fits in the cognitive-adaptogen landscape: it is the long-term memory consolidation compound, best suited for students during multi-month academic periods, professionals in information-dense work requiring long retention, older adults concerned about age-related cognitive decline, and users stacking with faster-acting cognitive enhancers as the chronic structural-maintenance component. It is not the right choice for users seeking acute pre-exam cognitive enhancement (that's rhodiola territory), for users with primary attention deficits (that's l-tyrosine or cholinergic precursors), or for users expecting rapid onset (that's caffeine + l-theanine, citicoline, or alpha-gpc). For a canonical long-form nootropic stack, Bacopa pairs with lion's mane (structural NGF-mediated neurogenesis), citicoline (acute cholinergic and membrane phospholipid support), and omega-3 EPA/DHA (phospholipid raw material and anti-inflammatory), producing a chronic cognitive-maintenance protocol supported by converging mechanisms. See also ashwagandha for stress resilience, rhodiola rosea for acute cognitive performance, and panax ginseng for the closest adaptogen analog.

Also known as: BLITZED

Dopaminergic nootropic used for focus and cognitive enhancement.

9-Methyl-β-carboline (9-MBC) is a synthetic β-carboline alkaloid that has gained significant interest in the nootropic community for its reported ability to promote dopaminergic neuron growth, increase dopamine synthesis enzymes, and provide neuroprotective effects against neurotoxins. It is one of the few compounds with preclinical evidence for actual dopaminergic neurogenesis rather than just release or reuptake modulation.

Noopept is the common brand and research name for N-phenylacetyl-L-prolylglycine ethyl ester (GVS-111; INN omberacetam), a small dipeptide nootropic developed in the 1990s at the Russian Academy of Medical Sciences' Institute of Pharmacology under Tatiana Voronina and Rita Ostrovskaya. Structurally, Noopept is a cyclized prolylglycine derivative conjugated to a phenylacetyl group, giving it roughly a thousand-fold higher potency than piracetam on a per-milligram basis while retaining some mechanistic overlap with the racetam family. It is sold over-the-counter in Russia as a cognitive enhancer and anxiolytic (trade name Noopept, manufactured by JSC Lekko Pharmaceuticals under license from the Zakusov Institute), where it carries approvals for post-concussive syndrome, cerebrovascular insufficiency, and mild to moderate cognitive decline. Outside Russia and a handful of CIS states, Noopept has no regulatory status — it is not approved as a drug in the United States, the United Kingdom, the European Union, Canada, or Australia, and it is not listed on any pharmacopoeia as a recognised medicine. It has been scheduled as a controlled or prohibited substance in a small number of jurisdictions (notably the Czech Republic) but in most Western countries it exists in a legal grey zone: neither an approved drug nor a regulated supplement, often sold online as a "research chemical" or nootropic powder. The compound's appeal rests on three overlapping claims — that it enhances memory consolidation, that it produces a mild anxiolytic effect, and that it is neuroprotective against oxidative, excitotoxic, and ischaemic insults. Each of these claims has some experimental support in rodent models and a small body of Russian clinical literature, but the evidence base is markedly thinner than for any drug approved in the West for cognitive impairment or anxiety. The key studies are mostly Soviet-era and post-Soviet Russian publications indexed on eLibrary.ru and — in a minority of cases — on PubMed, often with methodology that would not meet contemporary ICH-GCP or FDA standards. Randomised, double-blind, placebo-controlled trials with pre-registered endpoints, intention-to-treat analysis, and independent replication — the evidentiary bedrock of Western drug approval — are largely absent. This does not mean Noopept "doesn't work," but it does mean that anyone using it is relying on a body of evidence that would be considered hypothesis-generating rather than definitive by regulators at the FDA, EMA, MHRA, or Health Canada. For context, the drugs with the strongest evidence base for true cognitive impairment — Alzheimer's disease and related dementias — are the cholinesterase inhibitors donepezil, rivastigmine, and galantamine, and the NMDA receptor modulator memantine. These agents have been tested in thousands of patients in rigorously controlled trials and show modest but reproducible effects on cognition and activities of daily living. Newer disease-modifying therapies like lecanemab and donanemab target beta-amyloid pathology directly and have demonstrated reductions in cognitive decline in prodromal and mild Alzheimer's disease. Noopept is not a substitute for any of these drugs, and anyone experiencing genuine cognitive decline should be evaluated by a neurologist or geriatric psychiatrist rather than self-medicating with an unregulated Russian nootropic. For subclinical complaints — the "brain fog" and mild age-related cognitive slowing that prompt many healthy adults to try nootropics — the evidence for Noopept is weaker still. Most human trials were conducted in patients with documented cerebrovascular disease, post-traumatic cognitive impairment, or neurasthenic syndromes, not in healthy young adults seeking cognitive enhancement. Extrapolating from a 60-year-old Russian stroke patient to a 28-year-old programmer wanting sharper focus is a substantial leap that the data do not support. What Noopept offers healthy users — according to self-report and a handful of small Russian studies — is a subtle, often described as "subthreshold" improvement in mental clarity, mood, and stress tolerance, particularly when combined with an alcar/choline source to offset headaches. Whether this exceeds placebo in a properly blinded trial is an open question. Noopept's legal and regulatory status merits careful attention. It is unscheduled in the United States but is not recognised as a dietary supplement under DSHEA, meaning it is technically illegal to sell as a supplement though enforcement has been inconsistent. It is a prescription-only medication in Russia and several CIS states. In the European Union, it is generally treated as a novel food ingredient or an unregistered drug depending on the member state. It is banned or restricted in the Czech Republic, Hungary, and a few other countries. Anyone sourcing Noopept online should understand that they are purchasing an unregulated powder or capsule from a vendor whose quality control is unverifiable. Identity, purity, and dosing accuracy should be assumed to be uncertain unless third-party certificates of analysis (HPLC, mass spectrometry) are provided. Other nootropics in the same general category — selank and semax — share similar Russian origins and evidentiary limitations. For a more evidence-based approach to cognitive enhancement, see the literature on modafinil (prescription wakefulness agent with solid trial data for shift-work disorder and narcolepsy), methylene-blue, nad, or lifestyle interventions (sleep, exercise, nutrition) that have substantially more rigorous supporting evidence.

Also known as: Nootropil, Lucetam, Pirabene, UCB-6215, 2-oxo-1-pyrrolidineacetamide, 2-oxo-1-pyrrolidinylacetamide

Piracetam is the prototypical nootropic — the compound that inaugurated an entire class of cognitive enhancement drugs and gave the category its name. It was synthesized in 1964 by Romanian-born Belgian chemist Corneliu Giurgea at UCB Pharmaceuticals (Union Chimique Belge) as a chemical derivative of GABA, though paradoxically it has minimal direct GABAergic activity. Giurgea observed that piracetam produced cognitive enhancement without the sedation, stimulation, addiction potential, or toxicity of existing psychoactive compounds, and in 1972 he coined the term "nootropic" (from the Greek nous for mind and tropos for turning) specifically to describe compounds in piracetam's novel category. The defining Giurgean criteria for a nootropic — cognitive enhancement, resistance to hypoxia and injury, facilitation of learning, lack of typical psychopharmacologic side effects, and very low toxicity — were derived from piracetam's clinical profile and remain the reference standard by which other "nootropics" are evaluated. Piracetam has been approved in dozens of countries outside the United States for clinical indications including cortical myoclonus (particularly post-hypoxic myoclonus), age-related cognitive decline, vascular dementia in some jurisdictions, cognitive impairment following stroke, dyslexia in children (in certain European countries), alcoholic dementia, and vertigo. In Europe it is sold under brand names including Nootropil, Lucetam, and Pirabene. The US Food and Drug Administration has never approved piracetam for any medical indication, and in 2010 the FDA issued warning letters to companies marketing piracetam-containing products as dietary supplements, stating that piracetam is not a legal dietary ingredient under the Dietary Supplement Health and Education Act of 1994. Despite this regulatory position, piracetam remains widely available in the US through online retailers, research chemical vendors, and compounding pharmacies, operating in a legal grey area similar to several other nootropic compounds. The evidence base for piracetam spans 50+ years of continuous research with thousands of published studies ranging from rigorous randomized controlled trials in cortical myoclonus (where efficacy is well-established) to more heterogeneous trials in age-related cognitive decline (where a 2002 meta-analysis by Waegemans and colleagues found modest but statistically significant cognitive benefits), to controversial and largely negative trials for acute stroke and mild cognitive impairment. The mechanism of action remains partially obscure — piracetam modulates AMPA receptors, enhances membrane fluidity, increases cerebral blood flow, and has subtle effects on cholinergic and glutamatergic systems, but no single mechanism fully explains its clinical effects. What makes piracetam clinically distinctive is its notable safety profile: in 50+ years of clinical use it has produced essentially no reports of serious toxicity, no addictive potential, and no significant withdrawal syndrome, with a side effect burden limited mainly to occasional headache, mild GI effects, and rare psychological activation. This entry covers piracetam's mechanism of action and the ongoing uncertainty about which of its multiple pharmacologic effects drives cognitive enhancement; the clinical evidence base across cortical myoclonus, cognitive decline, stroke, and other indications; the US regulatory situation and its practical implications; the classic racetam side effect profile including the acetylcholine-depletion headache that motivates co-supplementation with choline sources; dosing conventions including the loading dose protocol favored by many users; how piracetam relates to and stacks with other nootropic compounds including Noopept, Modafinil, Sulbutiamine, Bromantane, Selank, Semax, Lion's Mane, Uridine Monophosphate, NAD+, Methylene Blue, L-Theanine, and L-Tyrosine; and what disciplined use of the founding nootropic looks like in the context of the modern cognitive enhancement landscape. Piracetam occupies a specific position in nootropic history and practice: not the most potent cognitive enhancer available, not the best-studied for any particular indication, but the compound with the longest safety track record and the broadest global clinical use as a general cognitive enhancement agent. For users seeking a gentle, well-tolerated, evidence-supported entry into cognitive enhancement pharmacology, piracetam remains a defensible first choice.

Phenylpiracetam is a Russian-developed phenyl derivative of piracetam with a dramatically higher potency and stimulant profile. Approved in Russia as Phenotropil/Carphedon for cognitive impairment and stroke recovery. Banned by WADA as a performance-improving drug due to its stimulant effects, significantly improving physical endurance in addition to cognition. One of the most potent and sought-after racetam family members.

Uridine monophosphate (UMP, also written 5'-UMP or uridine-5'-monophosphate) is the nucleotide form of uridine, consisting of the pyrimidine base uracil linked to a ribose sugar phosphorylated at the 5' position. It is one of the four building blocks of RNA (the others being adenosine monophosphate, guanosine monophosphate, and cytidine monophosphate) and serves as a precursor in multiple biochemical pathways central to membrane phospholipid synthesis, carbohydrate metabolism (as UDP-glucose, UDP-galactose), glycoprotein and glycolipid synthesis (as UDP-GlcNAc, UDP-GalNAc), and purinergic neurotransmission (through UDP and UTP acting on P2Y receptors). Food sources include liver (particularly calf and beef liver), fish (sardines, herring, anchovies), broccoli, beer yeast, and human breast milk — the last being notable because uridine is an abundant and biologically important constituent of mammalian breast milk, supplying developing infants with substantial nucleotide building blocks for rapid cell division and membrane synthesis during early growth. As a nootropic supplement, uridine monophosphate is primarily discussed in the context of cognitive function, mood, and neuroplasticity, based on its role as a substrate for the Kennedy pathway of membrane phosphatidylcholine synthesis. When supplemented orally at nootropic doses (typically 150-500 mg/day), uridine enters circulation, crosses the blood-brain barrier via specialised nucleoside transporters (ENT and CNT family), and is incorporated into brain cytidine triphosphate (CTP) — which is then condensed with choline (via choline kinase and CTP:phosphocholine cytidylyltransferase) to form CDP-choline, the activated intermediate used in phosphatidylcholine synthesis. Phosphatidylcholine is the predominant phospholipid of neuronal membranes and synaptic vesicles, and its availability is rate-limiting for the formation of new synapses during learning, memory formation, and neural repair. This mechanistic pathway — uridine provides the pyrimidine backbone for CDP-choline synthesis, which drives phosphatidylcholine production, which supports synaptic growth — is the central logical framework for uridine's nootropic use. It also explains why uridine is commonly stacked with a choline source (alpha-GPC, CDP-choline, or choline bitartrate) and with DHA (docosahexaenoic acid, an omega-3 fatty acid) — the three components together provide the pyrimidine, choline, and fatty acid substrates that collectively support membrane phospholipid synthesis. The Richard Wurtman group at MIT published substantial preclinical and clinical work in the 2000s and 2010s establishing this uridine-choline-DHA synergy and showing benefits in animal models of cognitive impairment and, in selected human populations, modest cognitive effects. The most clinically significant application has been as a component of Souvenaid (brand-name medical food containing uridine monophosphate, choline, DHA/EPA, phospholipids, B-vitamins, and antioxidants), studied in early Alzheimer's disease with moderate-quality data showing some benefit on memory composite scores in prodromal and mild Alzheimer's populations. Beyond the Alzheimer's-adjacent use, uridine has been studied and discussed in several other contexts: (1) major depressive disorder, particularly in work by Perry Renshaw and colleagues at McLean Hospital/Harvard on bipolar depression and unipolar depression, with some studies showing antidepressant signal; (2) bipolar disorder, with smaller studies suggesting potential benefit; (3) post-stroke cognitive recovery, with preliminary data; (4) pain syndromes including peripheral neuropathy, where pyrimidine nucleotide supplementation (cytidine + uridine) has been studied for nerve regeneration; and (5) general nootropic use in healthy adults, where the evidence is weakest and largely anecdotal. It is important to place uridine honestly in the therapeutic landscape. For Alzheimer's disease, the evidence-based treatments are cholinesterase inhibitors (donepezil, rivastigmine, galantamine), memantine, and the newer disease-modifying antibodies lecanemab and donanemab — all of which have substantially more rigorous trial evidence than uridine. Souvenaid (the uridine-containing medical food) has a modest evidence signal for prodromal/mild Alzheimer's but is not a replacement for approved therapies. For depression, the evidence-based treatments are SSRIs, SNRIs, and for treatment-resistant depression, ketamine/esketamine, TMS, and ECT. Uridine as monotherapy for depression is not evidence-based, but it has emerging data as a potential adjunct in bipolar depression. For general cognitive enhancement in healthy adults, the evidence is preliminary at best, and the best-evidenced interventions remain sleep, exercise, nutrition, and cognitive engagement. Where uridine has a genuine, reasonably well-supported role is: (1) as a component of the Souvenaid/uridine-choline-DHA stack for prodromal and mild Alzheimer's under physician guidance; (2) as a general supplement for membrane health and potentially mild cognitive support in older adults with concern about cognitive decline; (3) as an adjunct in bipolar depression under psychiatric supervision in research contexts; and (4) as a generally safe, low-risk nutritional supplement that forms part of various nootropic stacks without dramatic effects but also without significant risk when used sensibly. From a safety perspective, uridine is one of the safer supplements in the nootropic space. It is a naturally occurring nutrient present in ordinary dietary sources, including breast milk. Typical supplemental doses (150-500 mg/day) are multiples of ordinary dietary intake (dietary uridine is difficult to quantify precisely but typical Western diets provide perhaps 5-50 mg/day of free uridine plus substantial nucleotide-derived uridine), but well below toxic levels. Human studies with daily doses up to 2 grams have shown good tolerability. Gout is a theoretical concern because uridine is a purine-adjacent nucleotide and its metabolism produces allantoin and, through some pathways, uric acid — but in practice, supplemental uridine does not appear to cause clinically significant hyperuricemia at typical doses. Uridine is commonly combined with other nootropic compounds in community stacks: with choline sources (alpha-GPC, CDP-choline) for membrane synthesis support; with omega-3 DHA for the same purpose; with noopept or piracetam as part of broader cognitive-support stacks; with lions-mane for neurotrophic support; and with nad or other metabolic co-factors. The evidence for specific combinations is generally mechanistic/anecdotal rather than trial-validated.

Sulbutiamine (chemical name: isobutyryl thiamine disulfide; trade names include Arcalion, Enerion, Bisibutiamine) is a lipophilic synthetic derivative of vitamin B1 (thiamine), developed in Japan in the 1960s by Sankyo Company chemists who were seeking thiamine analogs with enhanced absorption and tissue penetration — particularly brain penetration. Structurally, sulbutiamine is a thiamine disulfide dimer in which two thiamine-derived moieties are linked by a disulfide bond and esterified with isobutyryl groups. This design makes sulbutiamine considerably more lipophilic than water-soluble thiamine hydrochloride, allowing it to cross lipid membranes (including the blood-brain barrier) more effectively than the parent vitamin. Once inside cells, sulbutiamine is reduced and hydrolysed to yield two molecules of thiamine, which then participate in normal thiamine biochemistry as thiamine pyrophosphate (TPP) — the active cofactor for pyruvate dehydrogenase, α-ketoglutarate dehydrogenase, branched-chain α-keto acid dehydrogenase, and transketolase. Sulbutiamine occupies an unusual regulatory position. It is an approved prescription medicine in France, several other European countries, parts of Asia, and various emerging markets, where it is indicated for treating asthenia (fatigue states) — a clinical concept that encompasses a range of fatigue syndromes, typically at doses of 400-600 mg/day. The French brand Arcalion is the most widely recognised form. In the United States, sulbutiamine is not FDA-approved as a drug and is not recognised as a dietary supplement under DSHEA, but it is not scheduled and is widely sold online as a nootropic/cognitive enhancer in powder and capsule form. In the United Kingdom, its status is ambiguous following the Psychoactive Substances Act 2016. In other jurisdictions, the legal status varies and users should verify locally before purchasing. The compound's appeal rests on four overlapping claims: (1) it may improve cognitive performance, particularly attention and memory, especially in the context of fatigue or mild asthenia; (2) it may reduce subjective fatigue; (3) it may have mild pro-cholinergic and pro-dopaminergic effects in addition to replenishing thiamine cofactor availability; and (4) it is generally well tolerated at therapeutic doses. Each of these claims has some experimental support, primarily from French clinical studies of asthenia and from a handful of PubMed-indexed rodent and human studies. The evidence base is larger than for many nootropic compounds but still modest compared with mainstream psychiatric or neurological medicines. It is important to place sulbutiamine honestly in the therapeutic landscape. For frank thiamine deficiency (beriberi, Wernicke's encephalopathy, dry or wet beriberi), the standard of care is intravenous or intramuscular thiamine hydrochloride at high doses — not sulbutiamine. Wernicke-Korsakoff syndrome requires emergency parenteral thiamine administration and is not an indication for oral sulbutiamine. For generalised fatigue without thiamine deficiency — the complaint most commonly prompting self-administration of sulbutiamine — the evidence-based approach is to evaluate for underlying causes (sleep disorders, depression, anaemia, thyroid dysfunction, chronic infection, autoimmune disease, cardiovascular disease, medication effects, substance use, psychosocial stressors) and treat the cause. Empiric treatment of fatigue with an oral thiamine derivative is, at best, a tertiary option after evidence-based causes have been excluded. For depression, evidence-based treatments include SSRIs, SNRIs, cognitive-behavioural therapy, and increasingly, rapid-acting agents like ketamine and esketamine for treatment-resistant cases — sulbutiamine is not a substitute for any of these. Where sulbutiamine may legitimately have a role is in the following contexts: (1) as an adjunct for patients with genuine asthenia in jurisdictions where it is approved and prescribed by a physician; (2) as an occasional cognitive/fatigue support supplement for healthy adults who have exhausted sleep, nutrition, and exercise optimisation; (3) potentially in the context of chronic fatigue syndromes (ME/CFS) or post-infectious fatigue, where evidence is preliminary but biologically plausible; and (4) in populations at risk for mild thiamine insufficiency — chronic alcohol use (though these patients need parenteral thiamine acutely), bariatric post-surgical patients, and some dietary restriction contexts. Sulbutiamine is often discussed alongside other nootropic B-vitamin derivatives such as benfotiamine (a different lipid-soluble thiamine derivative used primarily for diabetic neuropathy) and allithiamine (a related S-allyl thiamine found in garlic). Compared with benfotiamine, sulbutiamine is thought to have greater CNS penetration and more pronounced central cognitive effects, while benfotiamine is thought to produce higher peripheral thiamine levels with more benefit for diabetic neuropathy. These comparisons are mechanistic rather than head-to-head trial-based. Users interested in general cognitive enhancement may also see sulbutiamine discussed alongside noopept, selank, semax, piracetam, and choline sources like alpha-GPC and CDP-choline. As with any compound in the unregulated-supplement-or-prescription grey zone, sourcing matters. Prescription Arcalion obtained from a French or European pharmacy is a quality-controlled pharmaceutical product; sulbutiamine powder from an online supplement vendor may or may not be what the label claims. Users should favour either prescription supply or vendors providing third-party certificates of analysis (HPLC purity testing).

Also known as: Alpha-glycerophosphocholine, L-Alpha glycerylphosphorylcholine, Choline alfoscerate, GPC, α-GPC, Glycerylphosphorylcholine, Alpha GPC, Delecit, Gliatilin

Alpha-GPC (chemical name L-alpha-glycerylphosphorylcholine; pharmaceutical name choline alfoscerate) is a naturally occurring cholinergic compound that serves as a highly bioavailable precursor to both acetylcholine (the primary neurotransmitter of the cholinergic system, central to learning, memory, attention, and neuromuscular function) and phosphatidylcholine (the principal phospholipid building block of neuronal cell membranes). Chemically, Alpha-GPC consists of a glycerol backbone esterified at the sn-3 position with phosphate, which is in turn esterified to choline — this structure allows Alpha-GPC to cross the blood-brain barrier efficiently and deliver choline directly to central nervous system neurons, where it is cleaved by phospholipase D to release free choline and glycerophosphate. The released choline is then available for uptake by cholinergic neurons and conversion to acetylcholine by choline acetyltransferase (ChAT) within synaptic terminals. Alpha-GPC is found naturally in small amounts in human milk, soy, dairy, red meat, organ meats, and eggs, where it exists as a breakdown product of dietary phosphatidylcholine. The compound was first isolated and characterized in the 1950s-60s and entered pharmaceutical development in Europe in the 1980s. In Italy and several other European countries, Alpha-GPC is marketed as a prescription medication (brand names Delecit, Gliatilin, Brezal) for the treatment of cognitive impairment associated with stroke, transient ischemic attacks, and Alzheimer's-type dementia. In the United States, Alpha-GPC is regulated as a dietary supplement and medical food ingredient rather than a prescription drug, and is widely available in capsule, powder, and softgel forms. It is also used as an ingredient in some infant formulas and enteral nutrition products. In 2022, the European Food Safety Authority (EFSA) published a positive safety assessment of Alpha-GPC in food supplements, establishing its regulatory status as generally recognized as safe at typical supplemental doses. Alpha-GPC has become one of the most widely used cholinergic nootropics in the self-experimentation and cognitive enhancement community, where it is valued for several properties that distinguish it from other choline sources: (1) It shows superior bioavailability and brain penetration compared to bulk dietary choline, choline chloride, choline bitartrate, and citicoline (CDP-choline) in pharmacokinetic studies — with studies suggesting approximately 40% of orally administered Alpha-GPC reaches systemic circulation as intact compound capable of crossing the BBB. (2) It provides both acetylcholine precursor (choline) and membrane phospholipid precursor (glycerophosphate) in a single molecule, supporting both neurotransmitter synthesis and membrane repair. (3) It has a well-characterized clinical evidence base for mild cognitive impairment, vascular dementia, and post-stroke cognitive recovery, with decades of European prescription use providing substantial real-world safety data. (4) It has been evaluated in athletic performance contexts where choline availability becomes rate-limiting during prolonged high-intensity exercise (when plasma choline drops significantly) and in explosive power output contexts where maximal neuromuscular recruitment depends on acetylcholine release at the neuromuscular junction. Clinical evidence for Alpha-GPC is most substantial for mild-to-moderate cognitive impairment and for athletic performance applications. The key clinical trial — De Jesus Moreno Moreno 2003 (Clinical Therapeutics, PMID: 12637119) — enrolled 261 patients with mild-to-moderate Alzheimer's disease in a multicenter Italian trial and randomized them to Alpha-GPC 1200mg/day (400mg three times daily) versus placebo for 180 days. The Alpha-GPC group showed significant improvement on the ADAS-Cog (Alzheimer's Disease Assessment Scale-Cognitive Subscale), MMSE (Mini-Mental State Examination), and several functional and behavioral measures, while the placebo group showed continued decline consistent with expected disease progression. The effect size was clinically meaningful, and the between-group difference at 180 days was highly statistically significant. This trial remains the largest and most rigorous single study of Alpha-GPC for Alzheimer's disease and formed the rationale for the subsequent ASCOMALVA trial (Amenta and colleagues) testing Alpha-GPC added to donepezil versus donepezil monotherapy. For athletic performance and explosive power output, the key studies are Ziegenfuss et al. 2008 (Journal of the International Society of Sports Nutrition, a pre-PMID trial presented at the ISSN conference) which tested a single acute dose of Alpha-GPC 600mg versus placebo in trained athletes and observed significant improvements in isometric mid-thigh pull peak force, vertical jump performance, and upper-body power output — with peak effects occurring approximately 45-90 minutes post-ingestion, consistent with Alpha-GPC's pharmacokinetic profile. Bellar et al. 2015 (Journal of the International Society of Sports Nutrition, PMID: 26525523) randomized 13 college-aged males to Alpha-GPC 600mg or placebo for 6 days and measured lower body force production; Alpha-GPC group showed significantly greater isometric mid-thigh pull force than placebo. Parker et al. 2015 (Journal of the International Society of Sports Nutrition, PMID: 26092256) reported that Alpha-GPC supplementation increased post-exercise serum growth hormone levels — though the absolute magnitude was modest and the clinical significance of transient GH elevation is debated. A novel application that has emerged in the 2015-2022 period is potentiation of transcranial direct-current stimulation (tDCS) effects. Several published studies including Marcus et al. 2017 (Neurology, PMID: 28316031) investigated whether choline precursor supplementation could improve the cognitive benefits of tDCS in healthy adults and patients with mild cognitive impairment, with suggestive positive findings. This research remains preliminary but has contributed to growing interest in Alpha-GPC among users of at-home tDCS devices and in the broader brain-stimulation research community. Alpha-GPC is generally well-tolerated at typical doses of 300-1200mg/day. Common side effects include mild gastrointestinal upset (nausea, dyspepsia), transient headache (sometimes described as a "cholinergic headache" particularly at higher doses or in choline-sensitive individuals), dizziness, and occasional insomnia if dosed late in the day. A minority of users experience paradoxical mood effects (lowered mood, increased anxiety, or depression-like symptoms) that appear related to individual sensitivity to cholinergic stimulation — users with bipolar depression, major depressive disorder histories, or particular cholinergic-system vulnerabilities should approach Alpha-GPC with caution. A theoretical concern raised by a 2021 preprint (Ference et al. 2021, American Heart Association Conference) suggested possible associations between high-dose Alpha-GPC supplementation and cardiovascular events through trimethylamine-N-oxide (TMAO) metabolism pathways — this finding has been contested methodologically, has not been replicated in clinical trial data, and remains an open question rather than established risk. Users concerned about TMAO pathways may prefer CDP-choline which appears to generate less TMAO than Alpha-GPC. Practical positioning: Alpha-GPC is a cornerstone compound in many cognitive enhancement protocols — valued for acute cognitive sharpening (taken 30-90 minutes before demanding mental work), as a permanent addition to racetam stacks (particularly piracetam, noopept, aniracetam) to prevent the headaches characteristic of racetam-induced choline depletion, and for power output applications (taken 45-90 minutes pre-workout by strength and explosive-power athletes). It pairs well with natural cognitive enhancers including lion's mane (NGF/BDNF support), bacopa monnieri (memory consolidation), rhodiola rosea (fatigue and stress resistance), and L-theanine (attention without overstimulation). Many users find the optimal dose window is 300-600mg rather than pushing to the 1200mg clinical study dose, as the dose-response curve tends to plateau and higher doses increase side effect risk without proportional cognitive benefit.

Also known as: Citicoline, Cytidine 5'-diphosphocholine, Cytidine diphosphate-choline, Cognizin, Ceraxon, Somazina, Somazon, NeurAxon, CDPC

CDP-choline (cytidine 5'-diphosphocholine, pharmaceutical name citicoline) is a naturally occurring intracellular intermediate in the Kennedy pathway for phosphatidylcholine synthesis — the primary biochemical route by which all nucleated cells produce the dominant membrane phospholipid. Structurally, CDP-choline consists of cytidine (a pyrimidine nucleoside) linked via a diphosphate bridge to choline. When administered orally, CDP-choline is rapidly hydrolyzed in the gastrointestinal tract to its two constituent components — cytidine and choline — both of which are independently absorbed, cross the blood-brain barrier via their respective transporters, and are subsequently reassembled intracellularly into CDP-choline within neurons and other tissues. The intact CDP-choline molecule itself has negligible bioavailability after oral dosing; the therapeutic activity of oral citicoline comes from the combined delivery of its two metabolic building blocks, each of which supports distinct downstream neurochemical functions. CDP-choline was first developed as a pharmaceutical agent in Japan in the late 1970s-1980s (brand names Nicholin, subsequently Cognizin for the proprietary Kyowa Hakko fermentation-produced form) and in Europe (brand names Ceraxon, Somazina, Somazon) as a treatment for ischemic stroke recovery, traumatic brain injury, vascular dementia, and age-associated cognitive decline. In these regions it remains a prescription medication available in oral, intramuscular, and intravenous formulations. In the United States, CDP-choline is regulated as a dietary supplement and medical food ingredient rather than a prescription drug, and the proprietary Cognizin form (a stabilized pharmaceutical-grade citicoline) is widely used in cognitive-enhancement supplements, often at doses of 250-500mg per capsule. In the cognitive-enhancement and nootropics community, CDP-choline occupies a distinctive niche alongside Alpha-GPC, the other premium cholinergic precursor. Users often approach the two as complementary rather than competitive: Alpha-GPC provides highly bioavailable choline with superior acute CNS penetration (favored for acute pre-workout, pre-task, and short-term cognitive applications); CDP-choline provides choline plus cytidine (converted to uridine in humans), with the cytidine/uridine component offering independent benefits for neuronal membrane synthesis, synaptic function, and dopamine signaling beyond what Alpha-GPC provides (favored for long-term cognitive support, daily-use nootropic stacking, and applications where the uridine pathway is specifically relevant). CDP-choline also generates less trimethylamine-N-oxide (TMAO) than Alpha-GPC — a potentially important consideration for users concerned about the TMAO-cardiovascular hypothesis. The clinical evidence base for CDP-choline is more extensive than for any other cholinergic precursor, with decades of prescription use in Europe and Asia providing substantial real-world safety data and a strong body of randomized trial data across multiple indications. The single largest trial — ICTUS (International Citicoline Trial on acUte Stroke), Dávalos et al. 2012 (Lancet, PMID: 22841097) — randomized 2,298 patients with moderate-to-severe acute ischemic stroke to citicoline 2,000mg/day versus placebo for 6 weeks. The primary outcome (global recovery at 90 days) did not reach statistical significance (odds ratio 1.03, 95% CI 0.86-1.25), ending a 20-year period during which citicoline had been a standard European post-stroke treatment. The ICTUS result ended formal stroke indication for citicoline in many regulatory settings. However, secondary analyses and meta-analyses including Cochrane reviews have continued to identify possible subgroup benefits and modest effects in milder strokes, TBI, and age-related cognitive decline. For age-associated cognitive impairment and vascular dementia, the Fioravanti & Yanagi 2005 Cochrane review (PMID: 15846672) and its 2020 update included multiple randomized trials totaling hundreds of patients and concluded that citicoline produced modest improvements in memory, attention, and global cognitive performance in elderly patients with cognitive deficits — with effect sizes smaller than prescription cholinesterase inhibitors but with a more favorable side-effect profile. For cognitive enhancement in healthy adults, the Silveri et al. 2008 study (PMID: 18401325) used magnetic resonance spectroscopy to document that 6 weeks of citicoline 500mg or 2,000mg produced measurable increases in frontal-lobe phosphatidylcholine, phosphocreatine, and ATP levels — providing mechanistic support for claimed cognitive-enhancement effects. McGlade et al. 2012 (PMID: 22541339) randomized 60 adolescent females to citicoline 250mg, 500mg, or placebo for 28 days and observed dose-dependent improvements on attentional tasks (Ruff 2 & 7 Test) and reduced impulsivity on the Conners' Continuous Performance Test II. For traumatic brain injury, the COBRIT trial (Zafonte et al. 2012) in JAMA (PMID: 23168824) randomized 1,213 TBI patients to citicoline 2,000mg/day or placebo for 90 days and found no significant benefit on global functional or cognitive recovery — another large negative trial that further limited formal indications. Subsequent analysis of subgroups, however, has continued to support possible benefit in milder TBI, children, and populations different from the COBRIT enrollment. For ADHD, small trials have suggested cognitive improvements in attention and processing speed. For Parkinson's disease adjunctive use, citicoline has been explored based on its dopamine-precursor-sparing and neuroprotective properties; evidence is preliminary. For amblyopia and glaucoma, citicoline has been studied in European ophthalmology with some positive findings for visual evoked potentials and retinal ganglion cell function, and oral citicoline has become an accepted adjunct in some ophthalmology practices for these conditions. CDP-choline has an exceptionally favorable safety profile — multiple decades of European prescription use and extensive global supplement use have documented a very low rate of serious adverse events, minimal drug interactions, and good tolerability at doses up to 2,000mg/day. The most common side effects are mild gastrointestinal complaints and occasional headache; serious adverse events are rare. Unlike Alpha-GPC, CDP-choline has not been significantly associated with the 2021 cardiovascular/TMAO concerns, as less of the choline component is converted to TMA by gut bacteria in most studies. See also Alpha-GPC, Uridine Monophosphate, Omega-3 fatty acids, Piracetam, Noopept, Aniracetam, Lion's Mane, Bacopa Monnieri, Phosphatidylserine, Caffeine, and L-theanine for adjacent cognitive-support compounds and stacking context. This overview is educational only and is not medical advice.